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Main Text
The dominant pathway that mends two-ended DSBs, such as those created by programmable nucleases is NHEJ. NHEJ limits HR (also known as HDR, for homology-directed repair) first by being a fast-acting repair pathway that re-seals broken ends through a DNA ligase IV-dependent reaction 8 . Secondly, the Ku70/Ku80 heterodimer binds to DNA ends with high affinity, blocking their processing by the nucleases that generate the single-stranded DNA (ssDNA) tails that are necessary for the initiation of HR 8, 9 . A chromatin-based ubiquitin (Ub)-dependent signaling cascade 10 is also initiated by the detection of DSBs that modulates DSB repair pathway "choice" 11 . This pathway is largely controlled by a poorly understood antagonism between 53BP1, a pro-NHEJ factor, and BRCA1, the well-known breast and ovarian tumor suppressor and HR factor 11 . 53BP1 limits HR in part by blocking long-range DNA end resection but also by inhibiting BRCA1 recruitment to DSB sites 6, 12 .
To identify inhibitors of 53BP1, we took advantage of a soft-randomized library of ubiquitin variants (Ubvs) 7 that was initially developed to identify inhibitors of ubiquitin-binding proteins such as deubiquitylases. Since 53BP1 recognizes histone H2A ubiquitylated on Lys15 (H2AK15ub) in order to accumulate at DSB sites 13 , we reasoned that it might be possible to identify Ubvs targeting the 53BP1 UDR, the domain involved in ubiquitylated histone recognition 13 . After 5 rounds of selection against a GST-53BP1 fragment containing the tandem Tudor domain and UDR (residues 1484-1631; Fig. 1a ), 10 unique phages were selected for retesting in ELISA assays for binding to the Tudor-UDR region of 53BP1 and 14 other proteins, most of them known ubiquitin-binding proteins (Fig. 1b) . This process identified 5 distinct Ubvs that bound selectively to 53BP1 (A10, A11, C08, G08 and H04; Fig. 1bc ). We then generated
GST fusion proteins to 4 of these 5 Ubvs and tested them in GST pulldown assays against MBP 4 fused to either the Tudor domain (residues 1484-1603) or the Tudor-UDR fragment of 53BP1.
To our surprise, we observed that in addition to binding the UDR-containing protein, each Ubv bound to the MBP fusion containing only the 53BP1 Tudor domain (Fig. 1de ). Since the UDR is apparently not required for binding to the Ubv, all further experiments were carried out with proteins containing solely the Tudor domain. We selected clone G08 for further analysis because the phage expressing it displayed strongest binding by ELISA (Fig. 1b) and contained only 7 mutations, the lowest number of amino acid substitutions among the selected Ubvs (Fig. 1c) .
Since the 53BP1 Tudor domain binds to dimethylated histone H4 Lys20 (H4K20me2) 14 ,
we tested whether UbvG08-and H4K20me2-binding functions were mutually exclusive. We found that H4K20me2 peptides competed UbvG08 for 53BP1 binding with a half-maximal competing concentration in the100 µM to 300 µM range (Fig. 1f) . Since the dissociation constant (K d ) of the H4K20me2 peptide-53BP1 Tudor interaction is 20 µM 14 , the result of the H4K20me2 peptide competition implied that 53BP1 bound to UbvG08 with much higher affinity than methyl-lysine peptides. Indeed, as assessed by isothermal titration calorimetry (ITC), UbvG08 bind bound to the 53BP1 Tudor domain with K d of 242 +/-52 nM (N=3), two orders of magnitude tighter than the 53BP1-H4K20me2 interaction (Fig. 1g) . In contrast, a version of UbvG08 that reverted the L69P and V70L mutations to wild type (mutant DM; see below for the rationale behind these mutations) did not display any detectable binding to the 53BP1 Tudor domain by ITC (Fig. 1g ).
To gain insight into the mechanism by which UbvG08 binds to 53BP1, we solved the crystal structure of UbvG08 bound to the 53BP1 Tudor domain (see Methods for protein expression, crystallization, and structure determination details). Within the solved complex, the Tudor domain of 53BP1 adopted a canonical mixed α-β fold identical to that reported in its apo state (1XNI; secondary structure RMSD of 1.0 Å) and in complex with a H4K20me2 derived peptide (2IG0; secondary structure RMSD of 1.1 Å) ( Supplementary Fig. 1a ). UbvG08 displayed the expected ubiquitin-like fold consisting of a five-strand β-sheet (β1-5) buttressed against a single α-helix (α1) and a short 3 10 helix. However, it harbored one notable difference from the canonical Ub fold: the register of strand β5 was shifted 4 positions from its expected position, resulting in an increase in the length of the loop preceding strand β5 by 4 residues and a shortening of the C-terminal tail of β5 by 4 residues (Supplementary Fig. 1bc ).
Complex formation was achieved by association of the β-sheet surface of UbvG08 centred on β1, β2 and β5, with the ligand-binding surface of the 53BP1 Tudor domain (Fig. 2a ).
This surface on the Ubv is adjacent to but distinct from the I44-centred hydrophobic patch that mediates the majority of Ub-protein interactions 15 . The contact surfaces were extensive (buried surface area=755.4 Å 2 ), and comprised of a mixture of hydrophobic and hydrophilic residues (Fig. 2b) . Notable interactions include: 1) a hydrophobic cluster involving Tudor domain residues Y1500, F1553 and I1587 and UbvG08 residues L2, F4 and L70; 2) a network of salt and hydrogen-bonding interactions linking Tudor domain residues Y1502 and D1521 and UbvG08 residues T12 and K6; 3) a salt bridge between the Tudor domain residue E1551 and UbvG08 residue R72; 4) another salt bridge between Tudor domain residue E1575 and UbvG08 residue K66; 5) a hydrophobic interaction between Tudor domain residue Y1552 that packs against UbvG08 residues F45, P69 and L67 (Fig. 2c) .
The high-affinity binding between UbvG08 and the Tudor domain of 53BP1 can be rationalized as follows. Whereas the sequence of UbvG08 differs from wild type ubiquitin by 7 residues, only 4 substitutions are well positioned on the contact surface to allow direct interaction of their side chains with 53BP1. Specifically, L70 (Val in Ub) forms favourable hydrophobic contacts with 53BP1 F1553 and L1547; L2 (Gln in Ub) forms favourable hydrophobic contacts with 53BP1 Y1500; and P69 (Leu in Ub) forms favourable hydrophobic contact with 53BP1 Y1552 (Fig. 2c) . Additionally K66 (Thr in Ub) is well positioned to form an electrostatic interaction with 53BP1 E1575 (Fig. 2c) .
Other substitutions in UbvG08 may contribute to enhanced binding indirectly by stabilizing a shift in the register of strand β5. The L62 mutation (Gln in Ub) appears most important, as it resides at the initiating position of the normally tight loop preceding β5 in Ub ( Supplementary Fig. 1d ). The L62 substitution causes a reorientation of the side chain from a solvent-exposed orientation (in Ub) to a buried position (in UbvG08) in the hydrophobic core, which would be disruptive to tight turn formation. Additionally, the substituted side chains of D64 (Glu in Ub) and K66 (Thr in Ub) occupy new positions in the enlarged solvent-exposed loop preceding β5, whereas in the absence of a register shift, they would occupy positions in strand β3 directly facing the Tudor domain where they might otherwise contribute suboptimal interactions with 53BP1 ( Supplementary Fig. 1e ). The register difference in strand β5 adds an additional layer of complexity due to the non-substituted R72 side-chain displaced by 17 Å from its expected position in Ub, allowing it to form a near ideal salt interaction with E1551 in the Tudor domain (Fig. 2c) . Finally, based on its position remote from both the contact surface with 53BP1 and strand β3 of the UbvG08, we predict that S49 (Gln in Ub) does not contribute materially to the binding affinity for 53BP1 (Fig. 2c) .
To validate the functional significance of features observed in the crystal complex, we interrogated the respective binding surfaces with site-directed mutagenesis. We first assessed the impact of individually reverting each of the 7 substitutions in UbvG08 to their Ub counterparts.
The L2Q, L62Q, D64E, P69L and L70V reversions all reduced UbvG08 binding to 53BP1 in 7 pulldown assays, with the P69L and L70V mutations having the strongest effect (Fig. 2d) .
Indeed, simultaneous reversions of P69 and L70 to their Ub counterparts (Ubv08-DM) completely abolished UbvG08 binding to the 53BP1 Tudor domain, as measured by ITC (Fig.   1g ). In a converse set of experiments, we found that the simultaneous mutation of the equivalent residues in Ub into their UbvG08 counterparts were sufficient to convert Ub into a robust 53BP1-binding protein, as measured in pulldown assays (Fig. 2e) . We also assessed the importance of the non-substituted (i.e. same as Ub) residues in UbvG08 (Fig. 2f) as well as the residues on the 53BP1 Tudor domain predicted by our model to be engaged in key interactions ( Supplementary Fig. 2ab ). These analyses strongly validated the structural model of the UbvG08-53BP1 interaction.
We next tested whether intracellular expression of UbvG08 could inhibit 53BP1 in cells.
We prepared Flag-tagged versions of UbvG08 and the DM mutant. The C-terminal di-glycine motif was removed to preclude its incorporation in the active ubiquitin pool and we also incorporated a I44A mutation, which disables the majority of ubiquitin-dependent interactions 15 but does not impact the interaction of UbvG08 with 53BP1 (Fig. 2d ). This version of Ubv-G08 is referred to hereafter as inhibitor of 53BP1 or i53 for reasons that will become apparent below.
When U-2-OS (U2OS) cells transfected with vectors expressing i53 or its DM mutant were irradiated with a 10 Gy dose of X-rays, we observed that i53 but not the 53BP1-binding defective DM mutant strongly suppressed 53BP1 recruitment to DSB sites, as monitored by ionizing radiation focus formation (Fig. 3a,b) . The inhibition of focus formation was specific to 53BP1, as i53 did not impact γ-H2AX and BRCA1 focus formation ( Fig. 3a and Supplementary   Fig. 3a) . Transfection of i53 also induced BRCA1 accumulation at DSB sites in G1 cells 6 to a similar extent as that caused by loss of 53BP1 4, 6 , providing a first clue that i53 not only inhibits 8 53BP1 recruitment to damaged chromatin but also acts as an inhibitor of 53BP1 function ( Fig. 3c and Supplementary Fig. 3b ). i53, but not its DM mutant efficiently retrieved 53BP1 in coimmunoprecipitation experiments (Fig. 3d) suggesting that the inhibition of 53BP1 recruitment to DSB sites occurs through binding to 53BP1 and occlusion of the Tudor domain ligand binding site.
Loss of 53BP1 results in increased HR levels 16 , making inhibitors of 53BP1 potential tools to manipulate DSB repair pathways during genome engineering reactions. However, the depletion of 53BP1 by siRNA, while near complete as determined by immunoblotting ( Supplementary Fig. 4a ), is often insufficient to induce HR in the well-characterized directrepeat (DR)-GFP assay 17 ( Fig. 4b) . We therefore tested whether i53 impacted gene conversion frequency and observed that i53 led to a 2.4-fold (+/-0.25) increase in gene conversion when compared to the empty vector control, whereas the i53-DM mutant had virtually no impact on gene conversion (1.25-fold +/-0.17; Fig. 4c and Supplementary Fig. 4b ). As a point of comparison, we compared i53 to SCR7, the reported inhibitor of the NHEJ factor DNA ligase IV 18 , which has been shown in some systems to increase homology-dependent repair 19, 20 . We also tested its related pyrazine analog, which has been proposed to be the active SCR7 analog (https://www.tocris.com/dispprod.php?ItemId=432017#.VvUhqt-rSRs). i53 was a more potent inducer of gene conversion, compared to both SCR7 and to SCR7 pyrazine, which had minimal impact in this assay ( Fig. 4d and Supplementary Fig. 4c ). 53BP1 inhibition through i53 expression also stimulated gene conversion more robustly than 53BP1 depletion by siRNA ( Fig.   4b ). From these assays, we conclude that i53 stimulates gene conversion through the inhibition of 53BP1.
As an orthogonal approach, we also tested whether i53 expression increased the efficiency of gene targeting stimulated by CRISPR/Cas9. We took advantage of a recently described gene-targeting assay that involves the introduction of the coding sequence for a bright GFP variant, mClover, at the 5' end of the gene coding region for Lamin A (LMNA) 4, 21 (Fig. 4e) .
Gene targeting at the LMNA locus is not responsive to SCR7 treatment 21 , suggesting that endjoining may not provide a strong a barrier to HR at this locus. Similarly, inhibition of DNA-PK, a core NHEJ factor, with NU7441 only resulted in a modest increase in gene targeting in this assay ( Fig. 4f) . However, we observed that i53, but not the DM mutant, increased gene-targeting nearly two-fold (from 4.8% +/-0.5% for the empty vector control to 8.6% +/-0.6% for the i53 condition). The gene-targeting efficiency in i53-expressing cells approached that of 53BP1-null cells (53BP1Δ) 4 , suggesting that the inhibition of 53BP1 was near complete. Introduction of i53
in 53BP1Δ cells did not result in a further increase in gene targeting, demonstrating that the effect of i53 on HR is via inhibition of 53BP1. Finally, we found that combining DNA-PK inhibition and i53 led to an additive increase in gene targeting, consistent with 53BP1 modulating HR primarily through the regulation of DNA end resection rather than the efficiency of NHEJ.
Although UbvG08, the parent molecule of i53, shows a high degree of selectivity towards 53BP1 in ELISA assays (Fig. 1b) , we sought to determine the repertoire of cellular proteins bound by i53. We generated 293T Flp-In/T-Rex cell lines that expressed Flag-tagged i53 or i53-DM under the control of a tetracycline-inducible promoter as previously described 22 . Nine IP-MS experiments were analyzed (3 biological replicate IPs each for control, i53-and i53-DM expressing cell lines) and the interacting proteins were identified by MASCOT. The only protein found to interact with i53 in two or more experiments was 53BP1 (Table S2) . We conclude that i53 is a highly selective binder of 53BP1 in cells.
DNA end resection inhibits NHEJ but can activate alternative end-joining pathways in addition to activating HR 23 . Resection can reveal regions of microhomology that may be rejoined in a process termed microhomology-mediated end joining (MMEJ). MMEJ is a mutagenic process because it invariably leads to microdeletions or nucleotide insertions. To assess whether 53BP1 inhibition by i53 increases MMEJ, we employed the EJ2-GFP reporter assay 24, 25 . We found that i53 expression increased MMEJ (1.4 +/-0.2 fold over the empty vector; Supplementary Fig. 4de ) but since the expression of the DM mutant also increased MMEJ to a similar extent (1.3 +/-0.1 fold), it is unlikely that the modest increase in MMEJ observed following i53 expression was due to 53BP1 inhibition.
Finally, the use of precise genome editing by HR is currently hampered by the fact that cells in the G1 or G0 phase of the cell cycle are refractory to recombination. We recently elucidated the mechanism by which HR is inhibited in G1 cells and determined that reactivation of HR in G1 is possible through three distinct steps 4 : the inactivation of 53BP1, the restoration of the interaction between the HR factors BRCA1 and PALB2 (e.g. via depletion of KEAP1) and the activation of long-range resection through the expression of a phosphomimetic mutant of CtIP, CtIP-T847E 4 . We therefore assessed whether i53 could substitute for the genetic inactivation of 53BP1 to activate HR in G1. Remarkably, expression of i53 is nearly as efficient as the 53BP1 knockout in promoting Cas9-stiumulated gene targeting at the LMNA locus ( Fig.   4g ), suggesting that i53 could be included in an eventual strategy to stimulate HR in nondividing cells.
In summary, we report the development of a genetically encoded inhibitor of 53BP1 that robustly stimulates homology-directed repair of DSBs. The versatility of the ubiquitin scaffold onto which i53 is built, along with the determination of the molecular basis of the i53-53BP1 interaction should enable us to improve 53BP1 inhibition either through protein engineering or through affinity maturation of the UbvG08 via additional rounds of mutagenesis and phage display selections. Although an increase in the affinity of i53 may not be necessary for certain applications, we observed that low expression levels of i53 were insufficient to completely inhibit 53BP1. Indeed, lentiviral delivery of i53 only partially alleviated the poly(ADP-ribose) polymerase (PARP) inhibitor sensitivity in BRCA1-deficient RPE1-hTERT cells compared to a genetic deletion of 53BP1 ( Supplementary   Fig. 5ab ). Finally, DNA ligase IV inhibition by SCR7 18 was recently reported to stimulate homology-based genome editing 19, 20 . However, under our experimental conditions, we found i53
to be a more robust activator of HR than SCR7 or the DNA-PK inhibitor NU7441. Although we
have not yet tested whether i53 stimulates homology-dependent recombination of single-stranded oligonucleotide substrates, a reaction that appears to be responsive to SCR7 20 , we note that there might be safety concerns in the clinical use of DNA ligase IV inhibitors, as DNA ligase IV deficiency is associated with stem cell depletion and genome instability, especially in the hematopoietic stem cell compartment 27, 28 . We therefore propose that 53BP1 inhibition could be a propitious alternative for boosting HR rates.
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The phagemid (DDp2235) from the UbvG08 phage was obtained from the ubiquitin variant library described in 7 ; see below for details. The UbvG08 open reading frame (ORF) lacking the C-terminal di-Gly residues was cloned into a pDONR vector using a product from PCR amplification of the phagemid template and Gateway recombination, yielding plasmid DDp2251 (UbvG08 ΔGG). The pETM-30-2-GST-UbvG08 (DDp2186) and pETM30-2-GST-ubiquitin (DDp2192) were cloned following PCR amplification from the UbvG08ΔGG or UbΔGG ORFs, respectively. The constructs encoding His6-GST-TEV and MBP fusions of 53BP1 Tudor-UDR (residues 1484-1631) and Tudor (residues 1484-1603) domains were described previously in 13 .
The I44A mutation was introduced into DDp2186, which was then used as a template for amplification of the modified Ubv by PCR. The PCR product was cloned into the BamHI and NotI sites of a pcDNA3-Flag plasmid to yield pcDNA3-Flag-i53 (DDp2534). The BamHI-NotI fragment of DDp2534 was subsequently cloned into a pcDNA5-Flag-FRT/TO Flag vector to yield plasmid DDp2535. All other plasmids were generated by site-directed mutagenesis carried out by Quikchange (Agilent). The lentiviral vector coding for a siRNA-resistant Flag-tagged CtIP T847E construct was previously described 4 . The plasmids used for the LMNA assay were gifts of G. Dellaire 21 .
Single guide (sg)RNAs targeting TP53 (CAGAATGCAAGAAGCCCAGA), BRCA1
(AAGGGTAGCTGTTAGAAGGC) and 53BP1 (TCCAATCCTGAACAAACAGC) were cloned into lentiGuide-Puro (Addgene: #52963) as described 30 . The i53 and DM lentiviral expression vectors were prepared by PCR amplification that also introduced sequences coding for an Nterminal HA-tag and flanking PacI and NotI restriction sites. The PCR products were cloned in the PacI and NotI sites of pMX-IRES-GFP (a gift from A. Nussenzweig, National Institutes of Health). The Lenti-Cas9-2A-Blast construct was a gift from J. Moffat (University of Toronto).
All constructs were sequence-verified.
Selection of and purification of the 53BP1-binding ubiquitin variants
The phage-displayed Ubv library used in this study was re-amplified from Library 2 as previously described 7 . Protein immobilization and subsequent phage selections were performed according to established protocols 31 . Briefly, purified 53BP1 protein fragments were coated on 
Pulldowns
MBP and GST pulldowns were done essentially as described in ref 13 with the modifications described below. We used the following buffer for the binding reactions: 50 mM Tris-Cl pH 7.5, 50 mM NaCl, 0.01% NP40 and 1% BSA. We also used 2.5 µg of the MBP-and GST-fusion 
Protein expression, crystallization and structure determination
The 53BP1 Tudor domain (residues 1784-1603) and UbvG08 were individually expressed and purified from bacteria as GST-tagged fusion proteins. In brief, GST-tagged fusion proteins were purified from bacterial lysates on to glutathione-Sepharose (GE Healthcare), washed, and then eluted by TEV protease digestion to GST moieties, followed by purification by size exclusion and VariMax multilayer optics. Data processing was performed using the XDS software suite.
The structure of a single 53BP1 Tudor-UbvG08 complex in the asymmetric unit was solved by molecular replacement using the apo Tudor domain (PDB 2IG0) and ubiquitin (PDB 3NHE chain B) as search models in Phaser (Phenix suite). Structure refinement was performed using Refine (Phenix suite). See Table S1 for data collection and refinement statistics. 
Immunoprecipitation
RNA interference
All siRNAs employed in this study were single duplex siRNAs purchased from ThermoFisher.
RNA interference (RNAi) transfections were performed using Lipofectamine RNAiMax Except when stated otherwise, siRNAs were transfected 48 h before cell processing.
Inhibitors and fine chemicals
The following drugs and chemicals were used: DNA-PKcs inhibitor (NU7441; Genetex) at 10 µM, lovastatin (S2061; Selleck Chemicals) at 40 µM, doxycycline (#8634-1; Clontech), SCR7 (M60082-2; Xcessbio) at 1 µM. Olaparib was purchased from Selleck Chemicals.
Immunofluorescence microscopy
Cells were grown on glass coverslips, fixed with 2% (w/v) paraformaldehyde in PBS for 20 min at room temperature, permeabilized with 0.3% (v/v) Triton X-100 for 20 min at room temperature and blocked with 5% BSA in PBS for 30 min at room temperature. Cells were then incubated with the primary antibody diluted in PBS-BSA for 2 h at room temperature. Cells were next washed with PBS and then incubated with secondary antibodies diluted in PBS-BSA 20 supplemented with 0.8 µg ml −1 of DAPI (Sigma) to stain DNA for 1 h at room temperature. The coverslips were mounted onto glass slides with Prolong Gold mounting agent (Invitrogen).
Confocal images were taken using a Zeiss LSM780 laser-scanning microscope.
Reporter-based DNA repair assays
The direct repeat (DR)-GFP assay to measure the frequency of HR and the strand annealing EJ2-GFP assay to measure the frequency of MMEJ were performed as previously described 24 .
Briefly, U2OS DR-GFP or U2OS EJ2-GFP cells were transfected with 10 nM siRNA (Dharmacon) using Lipofectamine RNAiMAX (Invitrogen). 24 h later, the cells were transfected with the pCBASceI plasmid (Addgene #26477) and plasmids, using Lipofectamine 2000
(Invitrogen). 48 h post-plasmid transfection, the cells were trypsinized and the percentage of GFP-expressing cells was analyzed using the BD FACSCalibur flow cytometer.
The Lamin A (LMNA) assay to measure the frequency of introduction of the coding sequence for mClover at the 5' end of LMNA using the CRISPR/Cas9 was performed as previously described 4 . Parental or 53BP1Δ U2OS cell lines were transfected with the indicated plasmids using Lipofectamine RNAiMAX (Invitrogen). 24 h later, the cells were electroporated with 2.5 µg of sgRNA plasmids and 2.5 µg of donor template using a Nucleofector (Lonza; protocol X-001). Parental or 53BP1Δ U2OS cells stably expressing CtIP-T847E mutant were transfected with an siRNA against KEAP1 and the indicated plasmids and processed as previously described 4 .
Mass spectrometry
Following immunoprecipitation of Flag-tagged UbvG08 and UbvG08DM from HEK293 Flp-In/T-REx cells, peptides were identified using LC-MS/MS. Proteins were digested in solution with trypsin (Sigma, T7575-1KT) and dried to completeness. For LC-MS/MS analysis, peptides were reconstituted in 5% formic acid and loaded onto a 12-15 cm fused silica column with pulled tip packed in-house with 3.5 µm Zorbax C18 (Agilent Technologies, CA, USA).
UbvG08 and UbvG08-DM were analyzed using an LTQ (Thermo Scientific) coupled to an Agilent 1100 Series HPLC (Agilent Technologies). Peptides were eluted from the column using a 90 min period cycle with a linear gradient from 0% to 40% ACN in 0.1% formic acid. Tandem MS spectra were acquired in a data-dependent mode for the top 5 most abundant ions using collision-induced dissociation. Acquired spectra were searched against the human Refseq_V53 database using Mascot (Matrix Science).
Isothermal titration calorimetry
Isothermal titration calorimetry was performed using a VP-ITC calorimeter (MicroCal).
Untagged 53BP1 Tudor and UbvG08 (or the DM mutant) were dialyzed into PBS and degassed.
100 µM UbvG08 in the syringe was titrated into 10 µM 53BP1 Tudor protein in the sample cell using 30 consecutive 10 µl injections at 25 °C. Resultant binding isotherms were processed with Origin 5.0 software (Microcal). Curve fits were carried out using the one-set-of-sites model.
Olaparib sensitivity assays
Cells were seeded at a density of 20,000 cells/well in 6-well plates in the presence of olaparib at day 0. At day 4, the medium was refreshed with fresh inhibitor. At day 6, cells were collected by trypsinization and viable cell count was determined by Trypan blue exclusion using an automated cell counter (Vi-CELL, Beckman Coulter). T9  G10  K11 T12 I13   T14   L2  I3  F4  K6  L70  P69 H68 L67 
